Trials / Completed
CompletedNCT02082769
Safety and Efficacy of Oral Febuxostat in Subjects With Gout
A Phase 3, Randomized, Multicenter, Allopurinol-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 504 (actual)
- Sponsor
- Xijing Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare febuxostat allopurinol in subjects with gout.
Detailed description
A randomized, double-blind, multicenter, allopurinol-controlled and parallel-assigned study comparing 40 mg, 80 mg of febuxostat, and allopurinol 300 mg in subjects with gout. Subjects will receive treatment for 24 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Febuxostat | |
| DRUG | Allopurinol |
Timeline
- Start date
- 2011-07-01
- Primary completion
- 2013-10-01
- Completion
- 2013-10-01
- First posted
- 2014-03-10
- Last updated
- 2016-02-03
- Results posted
- 2016-02-03
Source: ClinicalTrials.gov record NCT02082769. Inclusion in this directory is not an endorsement.